

EFFECT OF T2DM ON INDUCING CHANGES IN VISFATIN LEVEL AND DETERIORATION IN CARDIAC FUNCTION

M.D THESIS PRESENTED BY

Marwa Abdeltawab Mohammed

Assistant lecturer Of physiology

(MB.BCH, MSC)

Faculty of Medicine ,Beni Sweif University

Under Supervision Of

Prof.Dr. Akef Khowailed

Professor of Physiology

Faculty of Medicine ,Cairo University

Dr.Mohammed Mansour

Lecturer of Physiology

Faculty of Medicine , Cairo University

Dr.Dina Abdelfatah

Assist. Professor Of Biochemistry

Faculty of Medicine ,Cairo University

Dr.Khalid Refaat

Lecturer Of Cardiology

Faculty Of Medicine ,Beni Sweif University

تأثير مرض السكري من النوع الثاني في إحداث تغيير في مستوى الفسفيتين وتدهور في وظائف القلب

رسالة دكتوراة مقدمة من

مروة عبد التواب محمد

مدرس مساعد الفسيولوجي

كلية الطب البشري

جامعة بني سويف

تحت إشراف

أ.د عاكف خويلد

أستاذ الفسيولوجي

كلية الطب البشري

جامعة القاهرة

د.دينا عبد الفتاح

د.محمد منصور

أستاذ مساعد الكيمياء الحيوية

مدرس الفسيولوجي

كلية الطب البشري

كلية الطب البشري

جامعة القاهرة

جامعة القاهرة

د.خالد رفعت

مدرس القلب والأوعية الدموية

كلية الطب البشري

جامعة بني سويف

Acknowledgement

I would like to thank Dr. Akel Khowiled for his greet advices and guides , he has a great experience in both science and life. I learnt a lot from him and I hope I will have a chance to learn more . I want also to thank Dr. Mohammed Mansour for his help and greet efforts in this study. Also I want to thank Dr. dina Abdelfatah for her help in the part concerning with biochemistry in this study. Finally I want to thank Dr. Khalid refaat for his useful guides .

INDEX

	Page Number
-List of figures.	i
-List of tables.	v
-Abbreviations.	vii
-Abstract	1
-Chapter (1)Diabetes Mellitus.	2
-Chapter (2)Cardiac complications	22
-Chapter (3)Adipokines	35
-Materials &Methods.	52
-Results.	82
-Discussion.	106
-Summary.	123
-References	125
-الملخص العربي-	174

List of Figures

	Page number
-Figure 1:illustration showing diabetic retinopathy	18
-Figure 2:Image of the fundus showing scatter laser surgery for diabetic retinopathy	19
-Figure 3: Nicotinamide phosphoribosyltransferase (Nampt) enzymatic activity.	39
-Figure4: Diagram summarizing the main reported actions of visfatin/Nampt/PBEF in the cardiovascular system.	44
-Figure 5: Main signaling pathways that mediate visfatin induced endothelial cell proliferation and migration.	46
- Figure 6 : Standard curve for cholesterol concentration calculation.	59
- Figure 7 :Standard curve for HDL concentration calculation.	62
- Figure 8: Triglyceride Standard Curve.	68
-Figure 9 :Standard curve for visfatin.	78
-Figure 10: Comparison of serum glucose between diabetic and control groups.	82
-Figure 11: Comparison of HBA1C between diabetic and control groups.	83

Figure 12: Comparison of BMI between diabetic and control groups	84
-Figure 13: Comparison of SBP between diabetic and control groups.	84
-Figure 14: Comparison of DBP between diabetic and control groups.	85
-Figure 15: Comparison of serum total cholesterol level between diabetic and control groups.	86
-Figure 16: Comparison of serum TG level between diabetic and control groups.	86
-Figure 17: Comparison of serum LDL level between diabetic and control groups.	87
-Figure 18: Comparison of serum HDL level between diabetic and control groups	87
- Figure (19): Comparison of serum visfatin level between diabetic and control group.	88
- Figure (20): Positive correlation between visfatin and serum glucose.	90
- Figure (21): Positive correlation between visfatin and HBA1C.	90

- Figure (22): Positive correlation between visfatin and total cholesterol.	91
- Figure (23): Positive correlation between visfatin and TG	91
-Figure (24): Positive correlation between visfatin and LDL	92
- Figure (25): Negative correlation between visfatin and HDL	92
- Figure (26): Positive correlation between visfatin and age.	93
- Figure (27): Positive correlation between visfatin and BMI.	93
- Figure (28): Positive correlation between visfatin and SBP.	94
- Figure (29): Positive correlation between visfatin and DBP.	94
- Figure (30): Positive correlation between visfatin and EF%.	95

- Figure (31): Comparison of EF% between diabetic and control groups.	96
- Figure (32): Negative correlation between EF% and glucose.	97
- Figure (33): Negative correlation between EF% and HBA1C.	97
- Figure (34): Negative correlation between EF% and total cholesterol.	98
- Figure (35): Negative correlation between EF% and TG.	98
- Figure (36): Negative correlation between EF% and LDL.	99
- Figure (37): Positive correlation between EF% and HDL.	99
- Figure (38): Negative correlation between EF% and BMI.	100
- Figure (39): Negative correlation between EF% and DBP.	100
- Figure (40): Negative correlation between EF% and SBP.	101

List of tables

	Page number
-Table 1:Measurement of serum glucose.	55
-Table 2:Dilution of Cholesterol Standard.	58
- Table 3:Contents of HDL kit.	61
-Table 4::Preparation of Triglycerides Standards.	65
-Table 5: Preparation of reaction mixture.	67
-Table 6: Comparison of serum glucose and HBA1c levels between diabetic and control groups.	82
Table 7: Comparison of BMI &SBP&DBP between diabetic and control groups	83
-Table 8: Comparison of serum total cholesterol&TG&LDL and HDL levels between diabetic and control groups.	85
- Table 9:Comparison of serum visfatin level between diabetic and control groups.	88
- Table (10a,b): Correlation between visfatin and other parameters.	89
- Table (11):Comparison of EF% between diabetic and control groups.	95
- Table (12a,b):Correlation between EF and other parameters.	96

-Table (13a):Summarization of statistical values for control females and diabetic females	102
-Table (13b):Summarization of statistical values for control males and diabetic males	102
- Table (14):Summerization of original values of age,sex,BMI,BP,EF% between control and diabetic groups.	103
-Table (15):Summerization of original biochemical values of visfatin,serum glucose,HBA1C for control and diabetic groups	104
- Table (16):Summerization of original biochemical values of total cholesterol,TG,LDL and HDL for control and diabetic groups	105

Abbreviations

ADA	American diabetes association
ADMA	Asymmetric dimethylarginine
AGEs	Advanced glycation end products
AVP	Arginine vasopressin
BMI	Body mass index
CAD	Coronary artery disease
CAN	Cardiac autonomic neuropathy
CD	Cluster of differentiation
CETP	Cholesterol ester transfer protein
CHD	Coronary heart disease
CVD	Cardio vascular diseases
DAN	Diabetic autonomic neuropathy
DDAH	Dimethylarginine dimethylaminohydrolase
DK A	Diabetic ketoacidosis
DM	Diabetes melitus
DSPN	Distal symmetric polyneuropathy
EASD	European Association for the Study of

	diabetes
eNOS	Endothelial nitric oxide synthase
ERK	Extracellular signal-regulated kinase
FGF	Fibroblast growth factor
GADA	Glutamic acid decarboxylase
	autoantibodies
GDM	Gestational diabetes mellitus
HAAF	Hypoglycemia-associated autonomic failure
HbA1c	Glycated hemoglobin levels
HF	Heart failure
HIF	Hypoxia-inducible factor
HNF1B	Hepatocyte nuclear factor 1 homeobox B
HNS	Hyperosmolar nonketotic state
HSL	Hormone-sensitive lipase
HUVEC	Human umbilical vein endothelial cell cultures
IA2	Insulinoma-associated2
ICA	Islet cell autoantibodies
IDF	International Diabetes Federation

IGF1	Insulin growth factor-1
IL	Interleukin
iNOS	Inducible nitric oxide synthase
LPL	Lipoprotein lipase
MAPK	Mitogen-activated protein kinases
MCP	Monocyte chemottractant protein
MHC	Major histocompatibility complex
MODY	Maturity onset diabetes of the young
MMP	Matrix metalloproteinases
mPTP	Mitochondrial permeability transition pore
NAD	Nicotinamide adenine dinucleotide
Nampt	Nicotinamide phosphoribosyltransferase
NF	Nuclear factor
NIDDM	Noninsulin-dependent diabetes mellitus
NMN	Nicotinamide mononucleotide
NO	Nitric oxide
NPDR	Non proliferative diabetic retinopathy
PAI-1	Plasminogen activator inhibitor 1
PARP	Poly(ADP ribose) polymerase
PBEF	Pre-B-cell colony-enhancing factor

PI3K	Phosphatidylinositol 3-kinase
PKC	Protein kinase c
ROS	Reactive oxygen species
SCF	Stem cell factor
STAT	Signal transducer and activator of transcription
SA-HRP	Streptavidin-horseradish peroxidase
TCF7L2	Transcription factor7 like 2
T2D	Type 2 diabetes
TIMP	Tissue inhibitors of MMP
TNF α	Tumor necrosis factor α
VEGF	Vascular endothelial cell growth factor
VSMC	Vascular smooth muscle cell
ZnT8	Zinc transporter8

Abstract

Background: Diabetes melitus is one of the most nutritional disorders associated with cardiovascular diseases . Visfatin is a new adipocytokine which is largely secreted by visceral adipose tissue and its effects in the development of diabetes and inflammatory reactions are similar to insulin. It acts synergistically with insulin in increasing glucose uptake, stimulating glucose transfer to the muscle and adipose tissue.

Methods: Glucose ,lipid profiles, visfatin ,ejection fraction were measured for 31 diabetics and 20 healthy people using usual biochemical methods , echocardiography for ejection fraction and sphygmomanometer for measurement of arterial blood pressure .

Results: The mean of body mass index,visfatin, total cholesterol, triacylglycerols, LDL-C and the fasting blood sugar levels,arterial blood pressure were highly significant in the diabetics as compared to those in the controls,while the mean HDL-C concentration and ejection fraction were significantly lower in diabetics than in controls.

Conclusion: High TC,TG,LDL,arterial blood pressure and decrease EF consider as an indicator that DM is properly associated with dyslipidemia and has high risk incidence of cardiovascular diseases, while high visfatin level in diabetics may give an idea about the role of visfatin in pathogenesis of DM.

Key words: Diabetes melitus,visfatin,lipid profiles,ejection fraction.